HDAC9 and head and neck squamous cell carcinoma: Another HDAC inhibitor, abexinostat, is being evaluated in combination with pembrolizumab in an actively recruiting phase 1b dose escalation study in patients with advanced solid tumors, including metastatic HNSCC (NCT03590054).